You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥(02552.HK)倒跌16%創上市新低
阿思達克 11-12 15:49
華領醫藥(02552.HK)公布研發中dorzagliatin(HMS5552)該股今天高開最多彈5.7%高見7.19元無以為繼,掉頭最多挫18.5%午後低見5.54元,創上市新低,現造5.73元,急挫16%,一向稀疏成交增至199萬股,為逾五個月最多。 華領公布,旗下研發中的雙重機制葡萄糖激(酉每)啟動劑dorzagliatin(HMS5552)的單藥治療III期臨床研究24周核心初步研究結果顯示,該藥有可能通過針對引起2型糖尿病的主要原因以治療2型糖尿病,修復血糖傳感、重塑血糖穩態,通過在胰島、肝臟和腸道發揮作用,調節胰島素、胰高糖素和GLP-1的分泌,促進血糖穩態平衡。不過,公司無法保證將於明年次季獲得52周臨床研究結果或可以成功開發或最終成功推出dorzagliatin。(sz/u)~ 阿思達克財經新聞 網址: www.aastocks.com
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account